A health condition index for assessing disease progression.

INTRODUCTION: Currently immunotherapy is considered a cutting edge pharmaceutical treatment for non-small cell lung cancer. Tumor profile plays a crucial role in identifying the correct patient group. METHODS: Therefore, initial biopsies and re-biopsies are necessary in order to identify the expression of programmed death-ligand-1. RESULTS: This information is crucial and therefore all future immunotherapy studies have to be built upon a specific statistical model which associates the tumor profile and tumor profile expression along with treatment efficiency. DISCUSSION: We present a novel statistical methodology for future immunotherapy studies of non-small cell lung cancer.